© 2019 Future Science Group

Unitec House, 2 Albert Place,

London, N3 1QB, UK

Email: info@future-science-group.com
Tel: +44 (0)20 8371 6090

  • LinkedIn - White Circle
  • Facebook - White Circle
  • Twitter - White Circle
  • YouTube - White Circle

News

January 09, 2018

Announcing the winner of the Bioanalysis Zone 2018 Bioanalysis Outstanding Contribution Award (BOSCA)

Bioanalysis Zone today announced the winner of the Bioanalysis Outstanding Contribution Award – BOSCA – awarded to bioanalytical scientists for outstanding work and contribution to the community.

 

The judges unanimously agreed that Jack Henion of Advion Inc. (NY, USA) was the most deserving of the title this year, due to his outstanding commitment, enthusiasm and research contributions to the advancement of bioanalysis.

 

Speaking to Bioanalysis Zone, Tom Covey (MDS/Sciex; MA, USA) commented: “[Jack’s] accomplishments are many, but what stands out was his brave voyage in 1985 from the old world of vacuum-based ionization to the new world of atmospheric pressure ionization for LC–MS, a relatively unknown place where very few dared to venture at that time. For this, he deserves to be known as the Christopher Columbus of LC–MS. When you consider it from that angle, it’s hard to come up with a single individual who has had as much of an impact on the field of LC–MS as Jack Henion.”

 

Richard King (PharmaCadence; PA, USA) added: “What I admire most is probably the fact that nothing is impossible. [He’s] been doing this [his] whole life, [he’s] contributed a huge amount to the field, and still, anything is possible. [He’ll] take on any challenge.”

 

Fellow bioanalysts also added their support, with Brad Ackermann (Eli Lilly and Company; IN, USA) remarking, “It really documents a lifelong commitment [he’s] had to our science,” and Eric Yang (GSK; London, UK) concluding: “Simply put, the bioanalysis community would not exist today without [the] groundbreaking work done in [his] lab decades ago.”

 

Bioanalysis and Bioanalysis Zone would like to extend their congratulations to Dr Henion, and thank him for the exceptional contributions that have led to the advancement of the bioanalytical field and community.

 

To celebrate the announcement of the 2018 BOSCA award winner, the following Bioanalysis articles have been made available free of charge to members of Bioanalysis Zone:

 

 

—END—

​  

 

 

About the Bioanalysis Outstanding Contribution Award

 

Launched in 2014, the Bioanalysis Outstanding Contribution Award (BOSCA) aims to recognize exceptional scientists who have not only contributed in a technical manner, namely advancing bioanalytical processes and our fundamental knowledge in the field, but also helped shape the community through their participation in societies, groups and the organization of conferences.

 

 

About Bioanalysis Zone

 

Since launching in 2011, Bioanalysis Zone has attracted over 9,000 active members from the global bioanalytical community, representing the pharmaceutical, biotech and CRO industries, along with academia and healthcare. Each month, thousands of members visit the site to read industry news, original research exclusive interviews, webinars and commentaries. Join the Bioanalysis Zone Twitter and LinkedIn group for updates.

 

 

About Bioanalysis

 

Bioanalysis is a MEDLINE-indexed journal covering the latest scientific, technical and regulatory developments relevant to those working on the analysis of xenobiotics and biotics in biological matrices. This is, primarily, bioanalysts working in pharmaceutical research and development, clinical laboratories, clinical toxicologists, forensic toxicologists and sports doping analysts.

 

 

​About Future Science Group

 

Founded in 2001, Future Science Group (FSG) is a progressive publisher focused on breakthrough medical, biotechnological, and scientific research. FSG’s portfolio includes two imprints, Future Science and Future Medicine. In addition to this core publishing business, FSG develops specialist eCommunities. Key titles and sites include Bioanalysis Zone, Epigenomics, Nanomedicine and the award-winning Regenerative Medicine.

 

The aim of FSG is to service the advancement of clinical practice and drug research by enhancing the efficiency of communications among clinicians, researchers and decision-makers, and by providing innovative solutions to their information needs. This is achieved through a customer-centric approach, use of new technologies, products that deliver value-for-money and uncompromisingly high standards.